NYSE:NVO - Novo Nordisk A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$43.50 +0.11 (+0.25 %)
(As of 10/17/2018 04:00 PM ET)
Previous Close$43.39
Today's Range$43.15 - $43.57
52-Week Range$41.23 - $58.37
Volume1.74 million shs
Average Volume1.54 million shs
Market Capitalization$115.19 billion
P/E Ratio18.50
Dividend Yield1.55%
Beta0.66
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration; and a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVO
CUSIPN/A
Phone45-4444-8888

Debt

Debt-to-Equity RatioN/A
Current Ratio1.17
Quick Ratio0.84

Price-To-Earnings

Trailing P/E Ratio18.50
Forward P/E Ratio17.26
P/E Growth2.49

Sales & Book Value

Annual Sales$16.96 billion
Price / Sales6.27
Cash Flow$2.3693 per share
Price / Cash18.36
Book Value$3.10 per share
Price / Book14.03

Profitability

EPS (Most Recent Fiscal Year)$2.34
Net Income$5.79 billion
Net Margins35.95%
Return on Equity83.32%
Return on Assets39.88%

Miscellaneous

Employees43,105
Outstanding Shares2,443,530,000
Market Cap$115.19 billion

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a special dividend on Thursday, August 9th. Investors of record on Monday, August 20th will be paid a dividend of $0.4669 per share on Tuesday, August 28th. This represents a dividend yield of 1.72%. The ex-dividend date is Friday, August 17th. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S announced that its board has approved a stock buyback program on Friday, February 2nd 2018, which permits the company to buyback outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its shares are undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) announced its earnings results on Wednesday, August, 8th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.64 by $0.04. The business had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.33 billion. Novo Nordisk A/S had a net margin of 35.95% and a return on equity of 83.32%. View Novo Nordisk A/S's Earnings History.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Wednesday, November 7th 2018. View Earnings Estimates for Novo Nordisk A/S.

What is the consensus analysts' recommendation for Novo Nordisk A/S?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novo Nordisk A/S.

Who are some of Novo Nordisk A/S's key competitors?

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 52)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 58)
  • Mr. Jesper Brandgaard, Exec. VP and Head of Biopharm & Legal Affairs (Age 55)
  • Ms. Liselotte Hyveled, Former Project VP for Faster-Acting Insulin Aspart & Prandial Bioedge Projects - Insulin & Director (Age 52)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 46)

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Saratoga Research & Investment Management (0.06%), Alta Capital Management LLC (0.04%), Scout Investments Inc. (0.02%), JLB & Associates Inc. (0.01%), Bank of Montreal Can (0.01%) and BB&T Corp (0.01%). View Institutional Ownership Trends for Novo Nordisk A/S.

Which major investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Saratoga Research & Investment Management, World Asset Management Inc, Webster Bank N. A., Bath Savings Trust Co, Winslow Evans & Crocker Inc., Cobiz Wealth LLC and North American Management Corp. View Insider Buying and Selling for Novo Nordisk A/S.

Which major investors are buying Novo Nordisk A/S stock?

NVO stock was purchased by a variety of institutional investors in the last quarter, including First Hawaiian Bank, Alta Capital Management LLC, Bank of Montreal Can, Fox Run Management L.L.C., Ipswich Investment Management Co. Inc., BB&T Corp, Gradient Investments LLC and JLB & Associates Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $43.50.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $115.19 billion and generates $16.96 billion in revenue each year. The company earns $5.79 billion in net income (profit) each year or $2.34 on an earnings per share basis. Novo Nordisk A/S employs 43,105 workers across the globe.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is http://www.novonordisk.com.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  341 (Vote Underperform)
Total Votes:  595
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2018 by MarketBeat.com Staff

Featured Article: Google Finance Portfolio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel